Auron Therapeutics and Elucidata Corporation recently announced a four year collaboration using Elucidata’s Polly. It is an AI-based target discovery platform to identify and validate targets for differentiation-based therapy for Acute Myeloid Leukemia (AML) and other oncology indications.

Elucidata will use Polly, to analyze transcriptomic, metabolomic and epigenetic data from biological samples along with treatment data from patients.

Read more on BusinessWire